🇺🇸 FDA
Patent

US 11926832

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

granted A61KA61K47/02A61K47/549

Quick answer

US patent 11926832 (Ketohexokinase (KHK) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K47/02, A61K47/549